Sun Pharmaceutical Industries Ltd. has announced that the shareholders of Organon & Co. have approved the proposals related to the previously announced merger transaction, marking a key milestone in the proposed acquisition.

Upon completion of the transaction, Organon is expected to become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA, Inc., an indirect wholly owned subsidiary of Sun Pharma.

The company said the shareholder approval brings the acquisition one step closer to completion. However, the deal remains subject to the fulfilment of customary closing conditions, including the receipt of required regulatory approvals.

Sun Pharma had first announced the proposed acquisition of Organon on April 27, 2026.